Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Jost

Showing results (191-200 of 202) with videos related to

Pageof 21
Sort By:
Nature Communications|September 11, 2020
MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeuticallyEnkhtsetseg Munkhbaatar, Michelle Dietzen, Deepti Agrawal, et al.
Nature Communications|March 16, 2024
Author Correction: Proteogenomic analysis reveals RNA as a source for tumor-agnostic neoantigen identificationCelina Tretter, Niklas de Andrade Krätzig, Matteo Pecoraro, et al.
Nature Communications|August 2, 2023
Proteogenomic analysis reveals RNA as a source for tumor-agnostic neoantigen identificationCelina Tretter, Niklas de Andrade Krätzig, Matteo Pecoraro, et al.
JCO Precision Oncology|February 9, 2022
Validating Comprehensive Next-Generation Sequencing Results for Precision Oncology: The NCT/DKTK Molecularly Aided Stratification for Tumor Eradication Research ExperienceAmelie Lier, Roland Penzel, Christoph Heining, et al.
European Journal of Cancer (Oxford, England : 1990)|June 28, 2022
Gene expression-based prediction of pazopanib efficacy in sarcomaChristoph E Heilig, Andreas Laßmann, Sadaf S Mughal, et al.
Cancer Cell|September 13, 2017
A Dual Role of Caspase-8 in Triggering and Sensing Proliferation-Associated DNA Damage, a Key Determinant of Liver Cancer DevelopmentYannick Boege, Mohsen Malehmir, Marc E Healy, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
17.6% of patients in a German cohort with exocrine pancreatic cancer were diagnosed with a genetic tumor syndrome-a case for universal genetic testing?D William, M Bermúdez, A Kübler, et al.
Cancer Discovery|June 11, 2021
Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare CancersPeter Horak, Christoph Heining, Simon Kreutzfeldt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 21, 2022
Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancersA Jahn, A Rump, T J Widmann, et al.
Cell Death and Differentiation|September 20, 2014
Essential versus accessory aspects of cell death: recommendations of the NCCD 2015L Galluzzi, J M Bravo-San Pedro, I Vitale, et al.
Pageof 21

Showing results (191-200 of 202) with videos related to

Sort By:
Pageof 21
Nature Communications|September 11, 2020
MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeuticallyEnkhtsetseg Munkhbaatar, Michelle Dietzen, Deepti Agrawal, et al.
Nature Communications|March 16, 2024
Author Correction: Proteogenomic analysis reveals RNA as a source for tumor-agnostic neoantigen identificationCelina Tretter, Niklas de Andrade Krätzig, Matteo Pecoraro, et al.
Nature Communications|August 2, 2023
Proteogenomic analysis reveals RNA as a source for tumor-agnostic neoantigen identificationCelina Tretter, Niklas de Andrade Krätzig, Matteo Pecoraro, et al.
JCO Precision Oncology|February 9, 2022
Validating Comprehensive Next-Generation Sequencing Results for Precision Oncology: The NCT/DKTK Molecularly Aided Stratification for Tumor Eradication Research ExperienceAmelie Lier, Roland Penzel, Christoph Heining, et al.
European Journal of Cancer (Oxford, England : 1990)|June 28, 2022
Gene expression-based prediction of pazopanib efficacy in sarcomaChristoph E Heilig, Andreas Laßmann, Sadaf S Mughal, et al.
Cancer Cell|September 13, 2017
A Dual Role of Caspase-8 in Triggering and Sensing Proliferation-Associated DNA Damage, a Key Determinant of Liver Cancer DevelopmentYannick Boege, Mohsen Malehmir, Marc E Healy, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
17.6% of patients in a German cohort with exocrine pancreatic cancer were diagnosed with a genetic tumor syndrome-a case for universal genetic testing?D William, M Bermúdez, A Kübler, et al.
Cancer Discovery|June 11, 2021
Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare CancersPeter Horak, Christoph Heining, Simon Kreutzfeldt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 21, 2022
Comprehensive cancer predisposition testing within the prospective MASTER trial identifies hereditary cancer patients and supports treatment decisions for rare cancersA Jahn, A Rump, T J Widmann, et al.
Cell Death and Differentiation|September 20, 2014
Essential versus accessory aspects of cell death: recommendations of the NCCD 2015L Galluzzi, J M Bravo-San Pedro, I Vitale, et al.
Pageof 21